The Arkansas Game and Fish Commission (AGFC) recently announced the first positive chronic wasting disease (CWD) test in a hunter-harvested deer in Union County, far from the nearest known positive finding in the state.
A study conducted in 15 hospitals found that discontinuing contact precautions for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) did not result in increased healthcare-associated infection (HAI) rates, researchers reported today in Infection Control & Hospital Epidemiology.
The World Health Organization (WHO) today recommended the RTS,S malaria vaccine for children in sub-Saharan Africa and other areas of moderate and high Plasmodium falciparum malaria transmission. The recommendation paves the way for global health groups to make funding and vaccine rollout plans and for countries to decide whether to include vaccination in their malaria control programs.
"Our findings suggest a potential risk of cross-border spread across Africa."
US veteran suicide ideation (SI) rates showed a slight decrease during the first year of the pandemic, according to a JAMA Psychiatry study yesterday. Among the associated risks, however, was having COVID-19, which doubled the odds of SI.
Moderna's COVID-19 vaccine was safe in adolescents 12 to 17 years old, with a similar immune response to that in young adults, according to results of an ongoing phase 2-3 trial published in the New England Journal of Medicine yesterday.
Republicans' intended COVID-19 vaccine uptake rose 7% after watching and reading endorsements from elite Republican leaders versus those from Democrat leaders, according to a study published yesterday in the Proceedings of the National Academy of Sciences.
Following China's 70-year battle against malaria, the World Health Organization (WHO) today announced that the country has been awarded a malaria-free certification. In a statement, the WHO said that the achievement is notable, given that China reported about 30 million cases each year in the 1940s.
The results of a phase 2b clinical trial indicate 77% efficacy over 12 months of follow-up for a vaccine that targets malaria caused by Plasmodium falciparum, according to a preprint study published this week in The Lancet.
Artemisinin-based treatment remains highly effective, but resistance mutations and delayed parasite clearance were found.